Announcement • Jun 30
Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2026 Results on Aug 25, 2026 Jointown Pharmaceutical Group Co., Ltd announced that they will report first half, 2026 results on Aug 25, 2026 Major Estimate Revision • May 04
Consensus EPS estimates fall by 19% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from CN¥0.521 to CN¥0.422 per share. Revenue forecast steady at CN¥171.6b. Net income forecast to grow 11% next year vs 13% growth forecast for Healthcare industry in China. Consensus price target broadly unchanged at CN¥5.81. Share price was steady at CN¥5.17 over the past week. Reported Earnings • Apr 28
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: EPS: CN¥0.14 (down from CN¥0.19 in 1Q 2025). Revenue: CN¥44.8b (up 6.6% from 1Q 2025). Net income: CN¥733.2m (down 24% from 1Q 2025). Profit margin: 1.6% (down from 2.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 3.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Apr 28
Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 21, 2026 Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 21, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei China New Risk • Apr 18
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Mar 30
Jointown Pharmaceutical Group Co., Ltd to Report Q1, 2026 Results on Apr 28, 2026 Jointown Pharmaceutical Group Co., Ltd announced that they will report Q1, 2026 results on Apr 28, 2026 Announcement • Dec 26
Jointown Pharmaceutical Group Co., Ltd to Report Fiscal Year 2025 Results on Apr 28, 2026 Jointown Pharmaceutical Group Co., Ltd announced that they will report fiscal year 2025 results on Apr 28, 2026 Reported Earnings • Oct 28
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: CN¥0.10 (up from CN¥0.092 in 3Q 2024). Revenue: CN¥38.2b (up 5.4% from 3Q 2024). Net income: CN¥529.9m (up 8.5% from 3Q 2024). Profit margin: 1.4% (up from 1.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 8.5%. Earnings per share (EPS) exceeded analyst estimates by 2.1%. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Jointown Pharmaceutical Group Co., Ltd to Report Q3, 2025 Results on Oct 28, 2025 Jointown Pharmaceutical Group Co., Ltd announced that they will report Q3, 2025 results on Oct 28, 2025 Major Estimate Revision • Aug 29
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from CN¥0.557 to CN¥0.501 per share. Revenue forecast steady at CN¥161.3b. Net income forecast to shrink 11% next year vs 24% growth forecast for Healthcare industry in China . Consensus price target broadly unchanged at CN¥6.21. Share price fell 6.2% to CN¥5.12 over the past week. Announcement • Jun 30
Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2025 Results on Aug 27, 2025 Jointown Pharmaceutical Group Co., Ltd announced that they will report first half, 2025 results on Aug 27, 2025 Declared Dividend • Jun 13
Dividend of CN¥0.20 announced Shareholders will receive a dividend of CN¥0.20. Ex-date: 17th June 2025 Payment date: 17th June 2025 Dividend yield will be 3.7%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (34% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 27% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 1.8% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • May 03
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.8% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • May 02
Full year 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.43 in FY 2023) Full year 2024 results: EPS: CN¥0.50 (up from CN¥0.43 in FY 2023). Revenue: CN¥151.8b (up 1.1% from FY 2023). Net income: CN¥2.51b (up 15% from FY 2023). Profit margin: 1.7% (up from 1.4% in FY 2023). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 6% per year. Announcement • Apr 29
Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 23, 2025 Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 23, 2025, at 10:00 China Standard Time. Announcement • Mar 28
Jointown Pharmaceutical Group Co., Ltd to Report Q1, 2025 Results on Apr 29, 2025 Jointown Pharmaceutical Group Co., Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 27
Jointown Pharmaceutical Group Co., Ltd to Report Fiscal Year 2024 Results on Apr 29, 2025 Jointown Pharmaceutical Group Co., Ltd announced that they will report fiscal year 2024 results on Apr 29, 2025 Price Target Changed • Nov 08
Price target decreased by 14% to CN¥6.41 Down from CN¥7.45, the current price target is an average from 3 analysts. New target price is 16% above last closing price of CN¥5.54. Stock is down 4.5% over the past year. The company is forecast to post earnings per share of CN¥0.43 for next year compared to CN¥0.43 last year. Reported Earnings • Oct 29
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.092. Revenue: CN¥36.3b (up 3.6% from 3Q 2023). Net income: CN¥488.5m (up 1.6% from 3Q 2023). Profit margin: 1.3% (down from 1.4% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in China. Announcement • Sep 30
Jointown Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024 Jointown Pharmaceutical Group Co., Ltd announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥5.25, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Healthcare industry in China. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥6.39 per share. Major Estimate Revision • Sep 04
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥168.3b to CN¥162.3b. EPS estimate also fell from CN¥0.523 per share to CN¥0.455 per share. Net income forecast to grow 31% next year vs 32% growth forecast for Healthcare industry in China. Consensus price target down from CN¥7.86 to CN¥7.69. Share price rose 5.3% to CN¥4.81 over the past week. Reported Earnings • Aug 27
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.15 in 2Q 2023). Revenue: CN¥36.7b (down 1.5% from 2Q 2023). Net income: CN¥670.0m (down 14% from 2Q 2023). Profit margin: 1.8% (down from 2.1% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Jun 28
Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024 Jointown Pharmaceutical Group Co., Ltd announced that they will report first half, 2024 results on Aug 27, 2024 Announcement • Jun 18
Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 300 million worth of its shares. Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of its shares. The shares will be repurchased at a purchase price of CNY 8.20 per share. The purpose of the program is to use the repurchased shares for the employee stock ownership plan. If the company fails to use the repurchased shares for the above mention purpose with in 3 years after the completion of the program, the unused shares will be cancelled. The program will be funded from company's own funds. The program will be valid for a period of 6 months. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to CN¥5.70, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Healthcare industry in China. Total loss to shareholders of 22% over the past three years. Major Estimate Revision • May 03
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥173.8b to CN¥168.1b. EPS estimate also fell from CN¥0.72 per share to CN¥0.64 per share. Net income forecast to grow 25% next year vs 32% growth forecast for Healthcare industry in China. Consensus price target of CN¥10.19 unchanged from last update. Share price was steady at CN¥8.21 over the past week. Announcement • May 01
Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 24, 2024 Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 24, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Wuhan, Hubei China Reported Earnings • Apr 28
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: EPS: CN¥0.14 (in line with 1Q 2023). Revenue: CN¥40.5b (down 3.8% from 1Q 2023). Net income: CN¥537.7m (down 4.2% from 1Q 2023). Profit margin: 1.3% (in line with 1Q 2023). Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Price Target Changed • Apr 11
Price target increased by 23% to CN¥9.48 Up from CN¥7.70, the current price target is an average from 3 analysts. New target price is 17% above last closing price of CN¥8.09. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥0.61 for next year compared to CN¥0.52 last year. Announcement • Mar 30
Jointown Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024 Jointown Pharmaceutical Group Co., Ltd announced that they will report Q1, 2024 results on Apr 27, 2024 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥8.21, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 18x in the Healthcare industry in China. Total returns to shareholders of 9.3% over the past three years. Announcement • Dec 30
Jointown Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024 Jointown Pharmaceutical Group Co., Ltd announced that they will report fiscal year 2023 results on Apr 27, 2024 Price Target Changed • Oct 29
Price target decreased by 10% to CN¥7.70 Down from CN¥8.60, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of CN¥7.44. Stock is up 24% over the past year. The company is forecast to post earnings per share of CN¥0.63 for next year compared to CN¥0.52 last year. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥1.16 (vs CN¥0.12 in 3Q 2022) Third quarter 2023 results: EPS: CN¥1.16 (up from CN¥0.12 in 3Q 2022). Revenue: CN¥35.0b (flat on 3Q 2022). Net income: CN¥480.7m (up 2.3% from 3Q 2022). Profit margin: 1.4% (up from 1.3% in 3Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Oct 11
Investor sentiment deteriorates as stock falls 30% After last week's 30% share price decline to CN¥7.56, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 17x in the Healthcare industry in China. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥9.35 per share. Price Target Changed • Sep 01
Price target increased by 15% to CN¥12.04 Up from CN¥10.48, the current price target is an average from 2 analysts. New target price is 20% above last closing price of CN¥10.05. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.87 for next year compared to CN¥0.72 last year. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.29 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.28 (down from CN¥0.29 in 2Q 2022). Revenue: CN¥37.3b (up 14% from 2Q 2022). Net income: CN¥781.8m (down 4.3% from 2Q 2022). Profit margin: 2.1% (down from 2.5% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Jun 28
Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023 Jointown Pharmaceutical Group Co., Ltd announced that they will report first half, 2023 results on Aug 29, 2023 Price Target Changed • Apr 29
Price target increased by 7.4% to CN¥15.62 Up from CN¥14.54, the current price target is an average from 2 analysts. New target price is 5.8% below last closing price of CN¥16.57. Stock is up 29% over the past year. The company is forecast to post earnings per share of CN¥1.30 for next year compared to CN¥1.08 last year. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.23 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.29 (up from CN¥0.23 in 1Q 2022). Revenue: CN¥42.1b (up 20% from 1Q 2022). Net income: CN¥561.2m (up 24% from 1Q 2022). Profit margin: 1.3% (in line with 1Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Price Target Changed • Mar 14
Price target increased by 8.5% to CN¥14.54 Up from CN¥13.40, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of CN¥14.84. Stock is up 20% over the past year. The company is forecast to post earnings per share of CN¥1.04 for next year compared to CN¥1.27 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. GM & Director Wei He was the last director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Nov 09
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from CN¥0.89 to CN¥1.03. Revenue forecast steady at CN¥138.1b. Net income forecast to grow 38% next year vs 13% growth forecast for Healthcare industry in China. Consensus price target of CN¥12.75 unchanged from last update. Share price was steady at CN¥12.78 over the past week. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.12 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.24 (up from CN¥0.12 in 3Q 2021). Revenue: CN¥35.0b (up 16% from 3Q 2021). Net income: CN¥469.7m (up 102% from 3Q 2021). Profit margin: 1.3% (up from 0.8% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Major Estimate Revision • Oct 21
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from CN¥0.89 to CN¥1.08. Revenue forecast steady at CN¥136.9b. Net income forecast to grow 51% next year vs 19% growth forecast for Healthcare industry in China. Consensus price target down from CN¥13.40 to CN¥12.75. Share price rose 3.1% to CN¥11.91 over the past week. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.77 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.43 (down from CN¥0.77 in 2Q 2021). Revenue: CN¥32.8b (up 12% from 2Q 2021). Net income: CN¥816.7m (down 42% from 2Q 2021). Profit margin: 2.5% (down from 4.8% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 15%, compared to a 18% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Major Estimate Revision • May 02
Consensus EPS estimates fall by 48% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥150.6b to CN¥137.7b. EPS estimate also fell from CN¥1.70 per share to CN¥0.89 per share. Net income forecast to shrink 12% next year vs 22% growth forecast for Healthcare industry in China . Consensus price target down from CN¥16.25 to CN¥13.40. Share price rose 5.2% to CN¥12.81 over the past week. Price Target Changed • Apr 28
Price target decreased to CN¥13.40 Down from CN¥16.25, the current price target is an average from 2 analysts. New target price is 10% above last closing price of CN¥12.17. Stock is down 28% over the past year. The company is forecast to post earnings per share of CN¥1.76 for next year compared to CN¥1.27 last year. Announcement • Apr 27
Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 600 million worth of its shares. Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces a share repurchase program. Under the program, the company will repurchase up to CNY 600 million worth of its shares. The program will be valid for a period of 6 months. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.23 (down from CN¥0.40 in 1Q 2021). Revenue: CN¥35.2b (up 7.7% from 1Q 2021). Net income: CN¥452.3m (down 41% from 1Q 2021). Profit margin: 1.3% (down from 2.3% in 1Q 2021). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 30%. Over the next year, revenue is forecast to grow 22%, compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥13.44, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.76 per share. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.48 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥30.1b (up 3.9% from 3Q 2020). Net income: CN¥232.7m (down 74% from 3Q 2020). Profit margin: 0.8% (down from 3.0% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 25
Second quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.37 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥29.4b (up 21% from 2Q 2020). Net income: CN¥1.41b (up 107% from 2Q 2020). Profit margin: 4.8% (up from 2.8% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Price Target Changed • Jul 27
Price target decreased to CN¥19.00 Down from CN¥21.35, the current price target is an average from 3 analysts. New target price is 37% above last closing price of CN¥13.89. Stock is down 22% over the past year. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.32 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥32.6b (up 20% from 1Q 2020). Net income: CN¥760.0m (up 32% from 1Q 2020). Profit margin: 2.3% (up from 2.1% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 04
New 90-day low: CN¥17.10 The company is down 6.0% from its price of CN¥18.24 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.67 per share. Price Target Changed • Jan 25
Price target raised to CN¥20.35 Up from CN¥18.93, the current price target is an average from 4 analysts. The new target price is 8.4% above the current share price of CN¥18.77. As of last close, the stock is up 14% over the past year. Is New 90 Day High Low • Nov 16
New 90-day high: CN¥18.60 The company is up 2.0% from its price of CN¥18.23 on 18 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥56.33 per share. Major Estimate Revision • Nov 02
Analysts update estimates The 2020 consensus earning per share (EPS) estimate increased from CN¥1.28 to CN¥1.43. Revenue estimate for the same period was approximately flat at CN¥109.6b. Net income is expected to shrink by 1.5% next year compared to 17% growth forecast for the Healthcare industry in China . The consensus price target of CN¥19.73 was unchanged from the last update. Share price stayed mostly flat at CN¥18.04 over the past week. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥2.85b, up 79% from the prior year. Total revenue was CN¥106.4b over the last 12 months, up 10.0% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 28
Annual earnings released: Earnings beat expectations Earnings per share (EPS) surpassed analyst estimates by 156% at CN¥0.46. Revenue is forecast to grow 15% over the next year, compared to a 36% growth forecast for the Healthcare industry in China. Announcement • Oct 20
Jointown Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020 Jointown Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2020 results on Oct 27, 2020 Announcement • Sep 22
Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million. Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire the remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million on July 6, 2020. On July 23, 2020, Shandong Buchang and Jointown Pharmaceutical formally signed the share transfer agreement. Within 10 working days after the signing of agreement, the buyer must pay the full transfer price to the designated account of the seller. In 2019, Hubei Buchang generated operating revenue of CNY 0.3 million and net loss of CNY 2.8 million. As at December 31, 2019, Hubei Buchang had total assets of CNY 36.4 million and net assets of CNY 36.3 million. As of July 6, 2020, Board of Directors of Shandong Buchang approved the transaction. Announcement • Jul 09
Jointown Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020 Jointown Pharmaceutical Group Co., Ltd. announced that they will report first half, 2020 results on Aug 25, 2020 
